Literature DB >> 8003002

Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-alpha.

C García-Martínez1, M Llovera, N Agell, F J López-Soriano, J M Argilés.   

Abstract

An acute intravenous administration of 100 micrograms/kg body weight of recombinant tumour necrosis factor-alpha resulted in a time-dependent increase in the levels of ubiquitin mRNAs in rat skeletal muscle. The results presented here, together with previous observations demonstrating that the cytokine increases the conjugation of proteins with ubiquitin in rat skeletal muscle (1), suggest that the ubiquitin system for non-lysosomal protein degradation could have a very important role in the mechanism triggered by tumour necrosis factor-alpha which is responsible for enhanced muscle proteolysis in sepsis and other pathological states.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8003002     DOI: 10.1006/bbrc.1994.1754

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  The role of Interleukin 15 in protein degradation in skeletal muscles in rats of chronic obstructive pulmonary disease.

Authors:  Zhaohui Liu; Wei Fan; Jinlong Chen; Zhike Liang; Lijun Guan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.

Authors:  M D Gomes; S H Lecker; R T Jagoe; A Navon; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 3.  The 20S/26S proteasomal pathway of protein degradation in muscle tissue.

Authors:  B Dahlmann; L Kuehn
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

4.  Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy.

Authors:  R Medina; S S Wing; A L Goldberg
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

Review 5.  Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia.

Authors:  D Attaix; L Combaret; T Tilignac; D Taillandier
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 6.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

Review 7.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Authors:  Erin E Talbert; Denis C Guttridge
Journal:  Semin Cell Dev Biol       Date:  2015-09-16       Impact factor: 7.727

8.  Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.

Authors:  Sílvia Busquets; Míriam Toledo; Enrica Marmonti; Marcel Orpí; Eva Capdevila; Angelica Betancourt; Francisco J López-Soriano; Josep M Argilés
Journal:  Oncol Lett       Date:  2011-10-13       Impact factor: 2.967

9.  Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice.

Authors:  T Tsujinaka; J Fujita; C Ebisui; M Yano; E Kominami; K Suzuki; K Tanaka; A Katsume; Y Ohsugi; H Shiozaki; M Monden
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

10.  Molecular and cellular mechanisms of skeletal muscle atrophy: an update.

Authors:  Alessandro Fanzani; Viviane M Conraads; Fabio Penna; Wim Martinet
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-06-07       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.